



ESCAIDE

European Scientific Conference on Applied Infectious Disease Epidemiology

19-21 November 2025 in Warsaw and online



Guidelines for abstract submission

General information

ESCAIDE 2025 will take place on 19-21 November 2025 as a hybrid event in Warsaw and online. The standard abstract call is open from 15 April to 14 May. A late breaker call will run from 10 to 24 September.

ESCAIDE 2025 welcomes abstracts from fields related to infectious disease and public health, including epidemiology, microbiology, virology, immunology, social sciences, science communication, the application of tools and methods to support infectious disease interventions, along with other relevant disciplines. We encourage submissions that inform public health actions, introduce innovative concepts, and bring new understandings to the field. Abstracts should be submitted in the form of text via the dedicated online platform: <https://abstracts.escaideconference.eu/>

Submit an abstract

Abstract submission process

Abstract ID number: After successful submission, a confirmation email will be sent to the submitting author and to the presenter (if different). This email will include the abstract reference number, which should be included in all correspondence related to the abstract.

Requests for changes: Corrections to abstracts can be made by 14 May 2025 (23:59 CEST), directly in the submission platform. After this deadline, no further changes will be accepted.

Responsibility of submitted content: The submitting author is responsible for ensuring the accuracy and quality of the abstract. If the abstract is accepted, any errors in spelling, grammar, or scientific content will be reproduced exactly as submitted.

Review and selection of abstracts: Each submitted abstract will be reviewed by three reviewers. The Scientific Committee may also assess abstracts that require further evaluation or a final decision on acceptance to the ESCAIDE 2025 programme. For details on the selection process and review criteria, please refer to the [Guidelines for abstract review and selection](#).

Communication of results: Notifications will be emailed to the submitting author and the presenter (if different) by 27 June 2025. Accepted abstracts will be assigned to respective sessions in the programme. Presenters are responsible for checking the date and time of their presentation and for registering for the conference.

Submission form

Create an account: The email address and password you choose will be used to log in to the abstract submission platform to create, edit and submit abstracts. Please ensure that this email address matches the one you will use to register for the conference.

Submission tracks: Tag each abstract with one Disease group and one Public Health function that best reflect its content. These selections are important, as they will be used to assign the abstract to reviewers with matching expertise.

Disease groups	Health functions
<ul style="list-style-type: none">• Antimicrobial resistance• Emerging and vector-borne diseases• Food- and waterborne diseases and zoonoses• Healthcare-associated infections• HIV/AIDS• Sexually Transmitted Diseases• Viral hepatitis B and C• Tuberculosis• Respiratory infections• Vaccine preventable diseases• General track: Public health sciences• General track: One Health	<ul style="list-style-type: none">• Burden of infectious diseases• Field epidemiology (e.g. outbreak investigations)• Evidence to policy and practice• International health and migration• Mathematical modelling and other quantitative methods• Microbiology• Novel methods (e.g. digital disease detection, e-Health, Artificial Intelligence)• Preparedness• Prevention• Social and behavioural sciences• Surveillance

Title: Choose a clear and informative title that reflects the main content of your abstract. Avoid using acronyms, as they may not be familiar to all readers. Do not write the title in all capital letters or capitalise the first letter of every word.

First author and co-authors: The submitting author will by default be added as the first author, but this can be changed if it is not the case. The authors will be listed in the order you enter them. If your abstract has multiple co-authors, please fill in all the required fields for each author. The co-authors will be listed in the order that you enter them.

Affiliations: When listing affiliations for authors, please only include the primary organisations they are affiliated with. If an author has multiple affiliations, please list them without numbering as the system will automatically organise them. To add affiliations, please use the format 'Full organisation name (Abbreviation)'. For example, 'European Centre for Disease Prevention and Control (ECDC)'. The country will be added in another field, so you do not need to repeat it here.

Consortium, network or group: If the abstract is co-authored by a consortium, network or group, please do not list all the co-authors and just give the name of the consortium, network or group.

Presenter: The submitting author will by default be added as the presenter, but this can be changed if it is not the case. The presenter of an accepted abstract must register for and attend the conference to ensure the abstract is presented. Please note that the presenters' email address entered must be the same one that will be used when registering for the conference.

Keywords: Please include four to six key words; use terms listed in the Medical Subject Headings (MeSH) from the Index Medicus (<http://www.nlm.nih.gov/mesh/>). Keywords should reflect core concepts of the abstract, including methods, results, and key findings, not just general topics. Select terms that complement, rather than duplicate, the title.

Abstract text: The total text should **not exceed 300** words (excluding the title). Abstracts must be written English, using UK English spelling. Please follow the structure of **Background, Methods, Results and**

Conclusions, but do not include these headings in the text. We encourage you to refer to the guiding questions provided in the [Guidelines for abstract review and selection](#), as reviewers will use the same criteria when assessing your submission.

Disclosure of the use of Artificial Intelligence (AI) tools: Authors must be transparent about any use of AI in the research or in drafting the abstract. If AI tools were used, please specify which tool and its purpose (e.g. language improvement, content generation, code writing, data processing) in the designated section of the submission form. The Scientific Committee reserves the right to exclude abstracts based solely on research conducted or generated by AI tools. Please note that AI tools cannot be listed as authors, as authorship requires accountability for the submitted work. All listed authors must review, edit, and assume full responsibility for the content of the abstract.

Declaration of originality: ESCAIDE abstracts should present original work that is recent and not yet in the public domain or presented at other conferences. Although abstracts based on previously published or multiple-conference submissions are discouraged, exceptions may be made if the work carries significant public health relevance. The decision to accept such abstracts is left at the discretion of the reviewers and the Scientific Committee, with priority given to original content of high public health importance. If the abstract includes material that has already been published or presented, this must be clearly disclosed in the designated section of the submission form, along with relevant links, if available.

Multi-country investigation/study: Please indicate if the abstract submitted is based on work involving at least two countries (e.g. cross-border investigation of an alert or an outbreak). Tick this box even if the abstract describes the background, methods, results and conclusions for only one of the countries involved.

Preferred presentation method: The final presentation format is determined by the review process and the Scientific Committee's decision, but you may indicate your preferred format:

- *Oral presentation:* If accepted, you will present your work during a Fireside session (options available for on-site and remotely).
- *Poster presentation only:* if accepted, your abstract will be considered exclusively for a poster. Posters must be submitted in advance through a dedicated platform. During the conference, they will be displayed on e-poster terminals and presented in a Poster tour. Please note that if your abstract is accepted as a poster, the presenter must attend in person, as remote poster presentations are not possible.

Considerations on diversity, equity and inclusion

Sex and gender: ESCAIDE recommends following the '[Sex and Gender Equity in Research - SAGER – guidelines](#)' and considering whether sex and/or gender play a role in your study design, data collection, analysis and reporting. Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully to avoid confusing them. If applicable, during your research ensure that data is disaggregated by sex and gender, and analyse and discuss any relevant differences.

Diversity in research: We encourage reflecting on the inclusiveness of your research approach and how diversity, across disciplines, geography, culture and ethnicity, may affect your findings and interpretations. These aspects may not apply to every study, but we invite you to consider them where relevant, including when planning future studies.

Balance of presentations: To support a wide range of voices at ESCAIDE, only one abstract per presenting author will be accepted. This helps create a balanced programme, reduces repetition and gives more researchers the opportunity to share their work. By limiting each presenter to one accepted abstract, we aim to encourage broader participation and showcase a wider range of perspectives.

Opportunities for funding

Are you an early career researcher working in the EU/EEA? The ESCAIDE Funding Initiative provides financial support for the attendance of selected abstract presenters. To check if you are eligible, please review the criteria on our website before indicating your eligibility in the abstract submission form. Applicants who express interest will be contacted at a later stage to provide additional information. Please note that funding is only available to presenters whose abstracts are accepted. [Find out more about the ESCAIDE Funding Initiative](#).

Important dates

Call for abstracts: 15 April–14 May

Review period: 16 May–4 June

Communication of results to authors: by 27 June

Call for late breakers: 10–24 September

Late breakers review period: 25 September–7 October

Communication of late breaker results to authors: by 15 October

ESCAIDE 2025: 19–21 November